In various malignancies, including breast, lung, and pancreatic adenocarcinomas, where PDPN is absent from tumor cells, the expression of PDPN in CAFs has been associated with metastasis, poor patient outcomes, and reduced overall survival [62–64]. The gene discussed is PDPN; the disease is neoplasm.